June 21 (Reuters) - AstraZeneca PLC:
* ASTRAZENECA PLC - EPLONTERSEN PH III TRIAL MET CO-PRIMARY ENDPOINTS
* ASTRAZENECA - NEW DRUG APPLICATION FILING ANTICIPATED BASED ON POSITIVE DATA FROM INTERIM ANALYSIS
* ASTRAZENECA - HIGH-LEVEL RESULTS SHOWED TRIAL ALSO MET ITS SECONDARY ENDPOINT
* ASTRAZENECA - ATTRV-PN IS EXPECTED TO BE FIRST INDICATION FOR WHICH ASTRAZENECA AND IONIS WILL SEEK REGULATORY APPROVAL FOR EPLONTERSEN Source text for Eikon: Further company coverage:
Our Standards: The Thomson Reuters Trust Principles.